Cancer‑screening firm Grail announced a $325 million private placement to fund commercial expansion, reimbursement push and working capital for its multi‑cancer detection Galleri blood test. The financing included new and existing institutional investors and follows an earlier strategic investment commitment from Samsung. Grail said proceeds extend its operational runway into 2030 and will support reimbursement negotiations and scale‑up of testing infrastructure. The capital raise underscores continued investor confidence in early‑detection platforms despite regulatory and payer complexities.